Maximum quantity allowed is 999
请选择数量
CAS RN: 872728-81-9 | 產品號碼: D6198
Dabigatran Etexilate Mesylate
×
![]()
×
純度/分析方法: >98.0%(T)(HPLC)
别名:
- Dabigatran Etexilate Methanesulfonate
- BIBR-1048MS
- Ethyl N-[[2-[[4-[N-[(Hexyloxy)carbonyl]carbamimidoyl]anilino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-(2-pyridinyl)-β-alaninate Methanesulfonate
文件：
* 以上價格已含運費關稅等但一些需要海運以及乾冰運輸的產品除外,詳情請與
當地經銷商
洽詢。
* TCI會時常優化儲存條件,儲存溫度請以在線目錄為準，敬請留意。
| 產品號碼 | D6198 |
純度/分析方法 
|
>98.0%(T)(HPLC) |
| 分子式 / 分子量 | C__3__4H__4__1N__7O__5·CH__4O__3S = 723.85 |
| 外觀與形狀（20°C） | Solid |
| 儲存條件
|
Refrigerated (0-10°C) |
| 儲存在惰性氣體下 | Store under inert gas |
| 應避免的情況 | Air Sensitive,Heat Sensitive |
| 包裝和容器
|
1G-Glass Bottle with Plastic Insert （閲覽圖片） |
| CAS RN | 872728-81-9 |
| Reaxys-RN | 15471668 |
| MDL編號 | MFCD17215180 |
產品規格
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Volumetric Analysis) | min. 98.0 % |
| NMR | confirm to structure |
性質
| 水溶性 | Insoluble |
| 溶解性（微溶於） | Ethanol |
GHS
| 圖形表示 |
|
| 信號詞 | Warning |
| 危險性說明 | H361 : Suspected of damaging fertility or the unborn child. H362 : May cause harm to breast-fed children. H373 : May cause damage to organs through prolonged or repeated exposure. |
| 防範說明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P263 : Avoid contact during pregnancy and while nursing. P260 : Do not breathe dust/ fume/ gas/ mist/ vapors/ spray. P270 : Do not eat, drink or smoke when using this product. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P405 : Store locked up. |
相關法規
| RTECS # | AY3157700 |
運輸資料
| HS編碼* | 2933.39-000 |
Application
Dabigatran Etexilate Mesylate: An Oral, Reversible Direct Thrombin Inhibitor
Dabigatran etexilate [D5904] and its mesylate are oral, reversible direct thrombin inhibitors and prodrugs of dabigatran [D5902]. Thrombin enables the conversion of fibrinogen into fibrin during the blood coagulation cascade. Inhibition prevents the formation of a thrombus. Therefore, thrombin-induced platelet aggregation is inhibited by the active metabolite dabigatran. It is used clinically as an alternative to warfarin [W0005] and does not require monitoring of coagulation parameters by blood tests. (The product is for research purpose only.)
References
- Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity (a review)
- Development of liquid chromatographic method for the analysis of dabigatran etexilate mesylate and its ten impurities supported by quality-by-design methodology
- Solubility measurement, correlation and molecular simulation of dabigatran etexilate mesylate polymorphs in five mono-solvents
產品文件 （部分產品的分析圖譜無法提供，敬請諒解。）
SDS
請選擇語言。
請求的SDS不可用。
如需更多幫助，請聯繫我們 。
產品規格
檢驗報告(CoA)及其他文檔
請輸入批號
輸入的批號不正確
示例 CoA
可下載CoA示例。注：該示例可能非最新批次的CoA。
目前沒有該產品的 CoA 示例。
分析圖譜
請輸入批號
輸入的批號不正確
很抱歉，您搜索的分析圖譜無法提供。